BCR::ABL1 emergence during menin inhibitor therapy in two patients with relapsed or refractory acute myeloid leukemia

Aaron Winer; Natalie Bennett; Emily Ferguson Mason; Ashwini K. Yenamandra; Robert Churchill; Alexis Froehlich; Jennifer Santos; Justin T. Kelley; Morgan L. Zenner; Sarah Profitt; Callee Brooks; Briaunna Minor; Nikith Kurella; Marium Hashemi; Kira Duvall; Ashwin Kishtagari; Kateryna Fedorov; Somedeb Ball

doi:10.1080/10428194.2026.2759552

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Over the past decade, molecular characterization has transformed prognostication and therapeutic decision-making in acute myeloid leukemia (AML) [1]. NPM1-mutated AML is a biologically distinct ent...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Winer et al. (2026) studied this question.

synapsesocial.com/papers/6af557d0b1e51a34e65a4c40 https://doi.org/10.1080/10428194.2026.2759552

View at Publisher

Ask AI

Bookmark

Share

BCR::ABL1 emergence during menin inhibitor therapy in two patients with relapsed or refractory acute myeloid leukemia

Ask about this paper

Abstract

Discussion

Cite This Study

BCR::ABL1 emergence during menin inhibitor therapy in two patients with relapsed or refractory acute myeloid leukemia

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading